Latest Medicine stories from Life.
In a significant move within the pharmaceutical industry, Angelini Pharma has announced its acquisition of Catalyst Pharmaceuticals, a company specializing in treatments for rare diseases, for $4.1 billion.
The Trump administration's recent actions regarding drug policy appear inconsistent, as the White House endorses treatment methods while imposing new restrictions.
La Trobe scientists have made a pivotal discovery in the fight against dangerous drug-resistant bacteria.
As discussions around pharmaceutical pricing evolve, the 'Most Favored Nation' model emerges as a potential solution worth considering for its implications and benefits.
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a substantial ad campaign aimed at the 340B drug discount program, highlighting its budget and focus.
Cytokinetics' heart disease treatment Myqorzo, which has prior approval for one indication, has now successfully met efficacy targets in a Phase 3 trial for a genetic heart condition.
Johnson & Johnson is proceeding with its inflammatory bowel disease therapy, even though recent trials did not demonstrate a statistically significant benefit for patients.
This editorial examines the collaboration between the U.S. government and Gavi, the Vaccine Alliance, focusing on their efforts to enhance immunization access in lower-income countries.
A recent discussion highlights medical students' views on the integration of preventive care education in their curriculum, revealing concerns about coherence in their training.
Julia Vintarello is embarking on a new biotech venture aimed at addressing the commercial and regulatory hurdles in the production of customized medicines.
Recent research suggests that compounds found in ginger and turmeric may help combat antibiotic-resistant infections, particularly affecting vulnerable groups.
Recent advancements in copper-based single-atom nanozymes may enhance precision in malignant tumor therapies while minimizing side effects.
The U.S. Department of Health and Human Services (HHS) is appealing a ruling that impacts vaccine policy, following a lawsuit by the American Association of Pediatrics.
A new method for synthesizing polyfunctionalized biaryls without the use of transition-metal catalysts has been introduced by researchers at the Institute of Science Tokyo.
A group of medical students emphasizes the importance of integrating nutrition into medical training, advocating for a shift toward preventive health education.
While modern medicine aims to improve health, it often overlooks the importance of patient comfort and emotional well-being, leading many to seek alternative options.
The FDA commissioner highlights how real-time clinical trials could change the landscape of drug development by providing regulators with immediate data insights.
Industry leaders express significant worries regarding the implications of Trump's drug pricing plan, while Purdue Pharma's sentencing underscores persistent challenges in the pharmaceutical sector.
A recent recommendation to limit hepatitis B vaccinations at birth to only those infants deemed at risk raises alarms about potential increases in infections among newborns.